You are here

ALS

Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program

Merck-backed VectorY Therapeutics raises $138M series A to push forward ALS program

Fierce Biotech

VectorY Therapeutics

Flag link:

BrainStorm lays off 30% of staff, slimming down for yet another bid to get ALS cell therapy to market

BrainStorm lays off 30% of staff, slimming down for yet another bid to get ALS cell therapy to market

Fierce Biotech

BrainStorm Cell Therapeutics

Flag link:

BrainStorm eyes FDA meeting to find path for rejected ALS drug after withdrawing application

BrainStorm eyes FDA meeting to find path for rejected ALS drug after withdrawing application

Fierce Biotech

BrainStorm Cell Therapeutics

Flag link:

Amylyx’s ALS drug knocked back again in Europe

Amylyx’s ALS drug knocked back again in Europe

BioPharma Dive

Amylyx Pharmaceuticals

Flag link:

FDA Adcomm Rejects BrainStorm’s ALS Therapy in Nearly Unanimous Vote

FDA Adcomm Rejects BrainStorm’s ALS Therapy in Nearly Unanimous Vote

BioSpace

BrainStorm Cell Therapeutics

Flag link:

AcuraStem and Takeda Partner to Revolutionize ALS Treatment

AcuraStem and Takeda Partner to Revolutionize ALS Treatment

Best Stocks

Flag link:

FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show

FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show

BioPharma Dive

Brainstorm Cell Thearpaueics

Flag link:

ALS advocates say criticism of new drugs misses bigger picture

ALS advocates say criticism of new drugs misses bigger picture

Stat

drug development

Flag link:

Clene polishes tarnished ALS asset with long-term survival data

Clene polishes tarnished ALS asset with long-term survival data

Fierce Biotech

clinical trials

Flag link:

Amylyx ALS drug sales tick higher after fast US launch

Amylyx ALS drug sales tick higher after fast US launch

BioPharma Dive

Flag link:

Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease

Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease

BioSpace

neurodegenerative disease

Alzheimer's disease

Axsome Therapeutics

BrainStorm Cell Therapeutics

Seelos Therapeutics

Parkinson's Disease

Mitsubishi Tanabe Pharma

Huntington's disease

Prilenia Therapeutics

Flag link:

Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker

Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker

Fierce Biotech

BrainStorm Cell Therapeutics

Flag link:

EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's ALS Treatment

EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's ALS Treatment

Benzinga

Amylyx Pharmaceuticals

Flag link:

Biogen teams with NeuroSense to explore ALS neurofilament biomarker

Biogen teams with NeuroSense to explore ALS neurofilament biomarker

BioSpace

NeuroSense Therapeutics

Flag link:

How ALS Cell Models That Began In Blood Spurred An Encouraging Early-Stage Clinical Trial

How ALS Cell Models That Began In Blood Spurred An Encouraging Early-Stage Clinical Trial

Forbes

clinical trials

Parkinson's Disease

Flag link:

FDA sets advisory meeting date for Brainstorm’s ALS cell therapy

FDA sets advisory meeting date for Brainstorm’s ALS cell therapy

BioPharma Dive

BrainStorm Cell Therapeutics

Flag link:

Quanterix sees a bright future for blood biomarkers

Quanterix sees a bright future for blood biomarkers

EP Vantage

Flag link:

Amylyx’s ALS drug could face rejection in Europe

Amylyx’s ALS drug could face rejection in Europe

BioPharma Dive

Flag link:

Apellis abandons ALS drug after study miss

Apellis abandons ALS drug after study miss

BioPharma Dive

Apellis Pharmaceuticals

clinical trials

Flag link:

Wave's ALS-dementia drug crashes out after early-phase flop, dealing further blow to target

Wave's ALS-dementia drug crashes out after early-phase flop, dealing further blow to target

Fierce Biotech

Wave Life Sciences

clinical trials

Flag link:

Pages